WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that Alise Reicin, MD, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference.

Morgan Stanley 24th Annual Global Healthcare Conference

The live fireside chat can also be accessed under “Events & Presentations” on the Investors section of the Tectonic website at www.tectonictx.com. Once the live event has concluded, a replay of the event will be available on the Company’s website for approximately 90 days.

The Tectonic management team will host one-on-one meetings during the conference. Interested investors should contact their Morgan Stanley representative to schedule meetings.

About Tectonic
Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow us on LinkedIn.

Contacts:

Investors:
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com

Media:
Kathryn Morris
The Yates Network
(914) 204-6412
kathryn@theyatesnetwork.com